Global X Management Co LLC cut its position in shares of Pfizer Inc. (NYSE:PFE) by 1.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 248,787 shares of the biopharmaceutical company’s stock after selling 2,563 shares during the quarter. Global X Management Co LLC’s holdings in Pfizer were worth $9,026,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in PFE. Charles Schwab Investment Advisory Inc. bought a new position in Pfizer during the second quarter worth about $286,229,000. Dimensional Fund Advisors LP lifted its stake in Pfizer by 15.0% during the second quarter. Dimensional Fund Advisors LP now owns 54,233,658 shares of the biopharmaceutical company’s stock worth $1,967,651,000 after purchasing an additional 7,059,171 shares during the period. Macquarie Group Ltd. lifted its stake in Pfizer by 20.7% during the second quarter. Macquarie Group Ltd. now owns 25,340,162 shares of the biopharmaceutical company’s stock worth $919,341,000 after purchasing an additional 4,344,595 shares during the period. Federated Investors Inc. PA lifted its stake in Pfizer by 110.5% during the second quarter. Federated Investors Inc. PA now owns 6,263,587 shares of the biopharmaceutical company’s stock worth $227,243,000 after purchasing an additional 3,287,377 shares during the period. Finally, Jensen Investment Management Inc. bought a new position in Pfizer during the second quarter worth about $110,291,000. 69.42% of the stock is currently owned by institutional investors and hedge funds.
NYSE:PFE opened at $44.98 on Friday. Pfizer Inc. has a 1 year low of $33.20 and a 1 year high of $46.47. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.15. The company has a market capitalization of $268.71 billion, a PE ratio of 16.97, a PEG ratio of 2.25 and a beta of 0.88.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.03. Pfizer had a net margin of 44.63% and a return on equity of 25.26%. The company had revenue of $13.30 billion during the quarter, compared to analysts’ expectations of $13.53 billion. During the same quarter in the previous year, the company posted $0.67 earnings per share. Pfizer’s quarterly revenue was up 1.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 3 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Monday, December 3rd. Stockholders of record on Friday, November 9th were paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date was Thursday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 51.32%.
PFE has been the subject of a number of analyst reports. Cantor Fitzgerald set a $45.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Thursday, October 4th. Morgan Stanley set a $45.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, August 29th. Goldman Sachs Group restated a “neutral” rating and set a $45.00 price target on shares of Pfizer in a research note on Tuesday, October 30th. Independent Research set a $48.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Thursday, October 4th. Finally, Credit Suisse Group set a $40.00 price target on shares of Pfizer and gave the stock a “hold” rating in a research note on Thursday, September 6th. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and nine have given a buy rating to the stock. Pfizer currently has an average rating of “Hold” and a consensus price target of $43.27.
In related news, major shareholder Pfizer Inc purchased 55,556 shares of the stock in a transaction that occurred on Monday, October 15th. The stock was acquired at an average price of $18.00 per share, with a total value of $1,000,008.00. Following the completion of the acquisition, the insider now directly owns 21,976,484 shares in the company, valued at approximately $395,576,712. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/12/07/global-x-management-co-llc-sells-2563-shares-of-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Featured Story: What is a Leveraged Buyout (LBO)?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.